Sequenom Posts 27 Percent Increase in Q1 Revenues, Cuts Loss

The firm's Center for Molecular Medicine has completed testing samples from a pivotal clinical validation study evaluating the performance of its SensiGene Trisomy 21 (T21) laboratory developed test and is on target for its launch late this year or early next year.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories